Singapore Med J 2009;50:265-9
It has shown efficacy in animal models of inflammatory bowel disease (IBD), gastric ulcers, and "leaky gut." Systemic anti-inflammatory effects: It appears to dampen inflammatory cascades without the immune-suppressing risks associated with corticosteroids
Pharmaceuticals GLP-1 Receptor Agonist Market GLP-1 Receptor Agonist Market Size, Trends, Share, Growth, and Regional Forecast, 2026 to 2033 GLP-1 Receptor Agonist Market by Product (Ozempic, Wegovy, Rybelsus, Victoza, Zepbound, Saxenda, Trulicity, Mounjaro, Others), Indication (Type 2 Diabetes mellitus, Obesity, Others), Route of Administration (Parenteral, Oral), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Regional Analysis from 2026 to 2033 December 2025 210 Pages Author : Abhijeet Surwase GLP-1 Receptor Agonist Market Share and Trends Analysis The global GLP-1 receptor agonist market size is estimated to grow from US$ 74.4 billion in 2026 to US$ 232.8 billion by 2033
Morgan & Morgan represents Bjorklund
